Filing identity and reporting period
The supplied filing is Nemus Bioscience, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2015, not a filing identified as Skye Bioscience, Inc. Nemus describes itself as a biopharmaceutical company developing cannabinoid-based therapeutics through a partnership with the University of Mississippi. It reported no revenue from planned operations.
Key financial metrics
| Metric | Three months ended March 31, 2015 | Comparable 2014 period |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $37,200 | $0 |
| General and administrative expense | $872,625 | $30,101 |
| Total operating expenses | $909,825 | $30,101 |
| Net loss | $910,225 | $30,101 |
| Basic and diluted loss per share | $0.06 | $0.00, rounded |
| Cash used in operating activities | $751,694 | $0 reported |
| Cash provided by financing activities | $721,069 | $0 |
At March 31, 2015, cash and cash equivalents were $176,705, current assets were $431,094, total assets were $468,729, current liabilities were $805,474, total liabilities were $807,085, and stockholders’ deficit was $338,356. The filing reports no interest paid; it does not identify material interest-bearing debt. Operating lease commitments totaled $381,700, with payments scheduled through 2017.
Material changes and financing
Operating expenses rose substantially from the prior-year quarter, primarily due to public-company-related consulting and professional fees, increased general and administrative costs, and new research activity. Net loss increased from $30,101 to $910,225. The quarter included $136,348 of employee stock-based compensation and $50,202 of amortization of warrants and stock issued for services in the cash-flow reconciliation.
Nemus raised $721,069 net from common-stock issuance during the quarter. In April 2015, after quarter-end, it sold preferred stock and warrants for $625,000. The company reported 16,265,663 common shares issued and outstanding at March 31 and as of May 12, 2015.
Outlook, risks, and unusual items
Management expected continued losses and significant research, development, public-company, staffing, and laboratory costs. It stated that, without additional funding, available funds would not be sufficient to meet obligations through December 2015 and disclosed substantial doubt about the company’s ability to continue as a going concern. Management planned to seek financing through equity or debt, collaborations, licensing, grants, asset sales, or other arrangements; availability and terms were uncertain, and equity financing could dilute shareholders.
Research was at an early stage, including a University of Mississippi project investigating cannabinoids as anti-infective therapeutics for MRSA. The filing highlights development and regulatory uncertainty, dependence on the university and other third parties, intellectual-property protection, competition, and the need for further funding. Nemus renewed an option to explore additional delivery routes for UM5050 on April 1, 2015. It reported no material legal proceedings and no changes to previously disclosed risk factors. Management concluded disclosure controls were effective at a reasonable assurance level.
Important facts for investors to verify
- Confirm the issuer: the provided text is a Nemus Bioscience, Inc. 10-Q, despite the request metadata naming Skye Bioscience, Inc.
- Review the April 2015 preferred-stock financing terms, related warrant issuances, and subsequent cash position; these occurred after quarter-end.
- Assess funding needs and the going-concern disclosure against the company’s cash burn, current liabilities, and lease commitments.
- Verify the status, milestones, costs, and licensing terms of the university research and product programs, and the potential dilution from equity awards and warrants.